ScreenerHero
ALTHXTHX Pharma Société Anonyme
EPA · FR · Healthcare · Biotechnology · theranexus.com
4.250EUR+1.55%Mkt Cap: 66.48M $P/E: —

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap66.48M $
Enterprise Value58.88M $
Revenue (TTM)876.14K $
Gross Profit-2.55M $
Net Income (TTM)-3.26M $
Revenue/Share0.0630 USD
Last Price4.250 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees12
CountryFR
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.33
PEG—
EV/EBITDA-13.75
EV/Revenue67.20
P/S76.68
P/B20.38
EPS (TTM)-0.22
EPS (Forward)-1.84
52W Range
1.49076% of range5.100
52W High5.100 EUR
52W Low1.490 EUR
Profitability
Gross Margin-177.00%
Oper. Margin-144876610.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-103.45%
ROA-28.46%
Growth
Revenue Growth-100.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-893.04K $
CapEx (TTM)279.60K $
FCF Margin-364.26%
FCF Yield-4.80%
Net Debt-5.31M $
Net Debt/EBITDA1.24
Balance Sheet
Debt/Equity0.99
Current Ratio2.35
Quick Ratio2.32
Book Value/Sh0.2100 EUR
Cash/Share0.5630 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)5.800 EUR
Upside (mean)+36.5%
Target Range5.800 EUR – 5.800 EUR
# Analysts1
Ownership
Shares Out.14.44M
Float13.13M
Insiders10.79%
Institutions7.93%
Technical
SMA 503.813 (+11.5%)
SMA 2003.026 (+40.4%)
Beta1.52
S&P 52W Chg18.16%
Avg Vol (30d)112.12K
Avg Vol (10d)129.74K
Technical Indicators
RSI (14)51.8
MACD0.1332
MACD Signal0.1778
MACD Hist.-0.0446
BB Upper4.759 EUR
BB Middle4.238 EUR
BB Lower3.717 EUR
BB Width24.60%
ATR (14)0.2454 EUR
Vol Ratio (20d)0.50x